The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Ocular Pharmacology and Therapeutics

• Publication date

  2017-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1089/jop.2017.0037PMID 28719234PMCID PMC5649393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glaucoma

  2018cited by this paper
• Positive allosteric modulation of CB1 suppresses pathological pain without producing tolerance or dependence

  2018cited by this paper
• Don't Worry, Be Happy: Endocannabinoids and Cannabis at the Intersection of Stress and Reward.

  2017cited by this paper
• Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB1.

  2017cited by this paper
• Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

  2017cited by this paper
• Cannabinoid receptor ligand bias: implications in the central nervous system

  2017cited by this paper
• Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.

  2017cited by this paper
• Microwave-accelerated Conjugate Addition of 2-Arylindoles to Substituted β-Nitrostyrenes in the Presence of Ammonium Trifluoroacetate: An Efficient Approach for the Synthesis of a Novel Class of CB1 Cannabinoid Receptor Allosteric Modulators

  2017cited by this paper
• Neuroprotection for treatment of glaucoma in adults.

  2017cited by this paper
• Theoretical Aspects of GPCR-Ligand Complex Pharmacology.

  2017influential reference
• Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor

  2017influential reference
• New strategies for neuroprotection in glaucoma, a disease that affects the central nervous system.

  2016cited by this paper
• The Endocannabinoid System as a Therapeutic Target in Glaucoma

  2016cited by this paper
• Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target

  2016cited by this paper
• Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model

  2016cited by this paper
• From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology.

  2016cited by this paper
• Seeing over the horizon – targeting the endocannabinoid system for the treatment of ocular disease

  2016cited by this paper
• Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural Update Review

  2016cited by this paper
• Crystal Structure of the Human Cannabinoid Receptor CB1.

  2016cited by this paper
• A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects

  2015cited by this paper
• Pharmacotherapy of Glaucoma

  2015cited by this paper
• Prolonged Monoacylglycerol Lipase Blockade Causes Equivalent Cannabinoid Receptor Type 1 Receptor–Mediated Adaptations in Fatty Acid Amide Hydrolase Wild-Type and Knockout Mice

  2014cited by this paper
• Congenital glaucoma as an ophthalmic manifestation of Frank–Ter Haar syndrome

  2014cited by this paper
• Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats

  2014cited by this paper
• In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569

  2014cited by this paper
• The pathophysiology and treatment of glaucoma: a review.

  2014cited by this paper
• The pathogenesis of glaucoma in the interplay with the immune system.

  2013cited by this paper
• Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat.

  2013cited by this paper
• Neuroprotection for treatment of glaucoma in adults.

  2013cited by this paper
• Status and perspectives of neuroprotective therapies in glaucoma: The European Glaucoma Society White Paper

  2013cited by this paper
• CB1 Receptor Allosteric Modulators Display Both Agonist and Signaling Pathway Specificity

  2013cited by this paper
• The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell neuroprotection in a rat model of optic nerve axotomy.

  2013cited by this paper
• Challenges in the development of glaucoma neuroprotection therapy

  2013cited by this paper
• The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model.

  2013cited by this paper
• Modulating the endocannabinoid system in human health and disease – successes and failures

  2013cited by this paper
• A GPR18‐based signalling system regulates IOP in murine eye

  2013cited by this paper
• Glaucoma

  2013cited by this paper
• The role of inflammation in the pathogenesis of glaucoma.

  2013cited by this paper
• Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs.

  2013cited by this paper
• Signaling cross-talk between cannabinoid and muscarinic systems actives Rho-kinase and increases the contractile responses of the bovine ciliary muscle.

  2013cited by this paper
• Emerging paradigms in GPCR allostery: implications for drug discovery

  2013cited by this paper
• Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma

  2012cited by this paper
• The molecular basis of retinal ganglion cell death in glaucoma.

  2012cited by this paper
• Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy.

  2012cited by this paper
• Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.

  2011cited by this paper
• Glaucoma.

  2011cited by this paper
• Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring

  2011cited by this paper
• Emerging drugs for ocular hypertension

  2011cited by this paper
• Anterior segment dysgenesis and early-onset glaucoma in nee mice with mutation of Sh3pxd2b.

  2011cited by this paper
• Indirect Sympatholytic Actions at β-Adrenoceptors Account for the Ocular Hypotensive Actions of Cannabinoid Receptor Agonists

  2011cited by this paper
• Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review

  2011cited by this paper
• Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system

  2010cited by this paper
• Measurement of Adherence to Brimonidine Therapy for Glaucoma Using Electronic Monitoring

  2010cited by this paper
• Disruption of the podosome adaptor protein TKS4 (SH3PXD2B) causes the skeletal dysplasia, eye, and cardiac abnormalities of Frank-Ter Haar Syndrome.

  2010cited by this paper
• Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

  2009cited by this paper
• The podosomal-adaptor protein SH3PXD2B is essential for normal postnatal development

  2009cited by this paper
• N-arachidonylethanolamide-induced increase in aqueous humor outflow facility.

  2008cited by this paper
• Targeting the endocannabinoid system: to enhance or reduce?

  2008cited by this paper
• Topical WIN55212-2 Alleviates Intraocular Hypertension in Rats Through a CB1 Receptor Mediated Mechanism of Action

  2008cited by this paper
• Comparison of Topical and Intravenous Administration of WIN 55-212-2 in Normotensive Rabbits

  2008cited by this paper
• Endocannabinoids in the retina: from marijuana to neuroprotection.

  2008cited by this paper
• Aqueous humor outflow effects of 2-arachidonylglycerol.

  2008cited by this paper
• Targeting the endocannabinoid system: to enhance or reduce?

  2008cited by this paper
• Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma.

  2007cited by this paper
• Agonist‐dependent cannabinoid receptor signalling in human trabecular meshwork cells

  2007cited by this paper
• Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats.

  2007cited by this paper
• Once daily drop regimes help reduce involuntary non-compliance.

  2007cited by this paper
• Neuroprotective and Intraocular Pressure-Lowering Effects of (–)Δ9-Tetrahydrocannabinol in a Rat Model of Glaucoma

  2007cited by this paper
• Allosterism and cannabinoid CB(1) receptors: the shape of things to come.

  2007cited by this paper
• Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle.

  2007cited by this paper
• Endocannabinoids and the regulation of their levels in health and disease

  2007cited by this paper
• Ocular Hypotensive Effects of an Intratracheally Delivered Liposomal Δ9-Tetrahydrocannabinol Preparation in Rats

  2006cited by this paper
• CB1 cannabinoid receptor-mediated changes of trabecular meshwork cellular properties.

  2006cited by this paper
• Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility.

  2006cited by this paper
• Simplification of eye drop regimes helps reduce involuntary non-compliance with glaucoma treatment

  2006cited by this paper
• Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study

  2006cited by this paper
• The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids

  2005cited by this paper
• Cannabinoid tolerance and dependence.

  2005cited by this paper
• Finding of endocannabinoids in human eye tissues: implications for glaucoma.

  2005cited by this paper
• Allosteric Modulation of the Cannabinoid CB1 Receptor

  2005cited by this paper
• Cannabinoid tolerance and dependence: a review of studies in laboratory animals.

  2005cited by this paper
• Stimulation of cannabinoid (CB1) and prostanoid (EP2) receptors opens BKCa channels and relaxes ocular trabecular meshwork.

  2005cited by this paper
• Cannabinoid agonists induce contractile responses through Gi/o-dependent activation of phospholipase C in the bovine ciliary muscle.

  2004cited by this paper
• Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite.

  2003cited by this paper
• Twenty-four-hour pattern of mouse intraocular pressure.

  2003cited by this paper
• Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys.

  2003cited by this paper
• Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

  2002cited by this paper
• Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides.

  2002cited by this paper
• The synthetic cannabinoid WIN55212‐2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies

  2001cited by this paper
• Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2.

  2000cited by this paper
• Pharmacology of the Intraocular Pressure (IOP) Lowering Effect of Systemic Dexanabinol (HU-211), A Non-Psychotropic Cannabinoid

  2000cited by this paper
• Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits.

  1998cited by this paper
• Marijuana smoking vs cannabinoids for glaucoma therapy.

  1998cited by this paper
• Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma.

  1997cited by this paper
• Ocular activity of topically administered anandamide in the rabbit.

  1997cited by this paper
• A Comparison of the Ocular and Central Effects of Δ9-Tetrahydrocannabinol and Cannabigerol

  1990cited by this paper
• A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol.

  1990cited by this paper
• Central nervous system and peripheral mechanisms in ocular hypotensive effect of cannabinoids.

  1987cited by this paper
• Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon?

  1975cited by this paper
• Effect of 1 -tetrahydrocannabinol on aqueous dynamics and ciliary body permeability in the rabbit.

  1973cited by this paper

• The Endocannabinoid System: Role in Ocular Physiology and Therapeutic Potential in Eye Diseases: A Narrative Review

  2025cites this paper
• Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.

  2025cites this paper
• Allosteric Modulation of Cannabinoid Type 1 Receptor by ZCZ011: Integration of In Vitro Pharmacology and Molecular Dynamics Simulation

  2025cites this paper
• Positive allosteric modulation of the cannabinoid CB1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics

  2024influential citation
• Cannabinoid receptor 1 positive allosteric modulator ZCZ011 shows differential effects on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice

  2024cites this paper
• Determination of the Cannabinoid CB1 Receptor’s Positive Allosteric Modulator Binding Site through Mutagenesis Studies

  2024cites this paper
• Could positive allosteric modulators of the cannabinoid CB1 receptor be efficacious and safe for the treatment of chronic pain?

  2024cites this paper
• Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present)

  2024cites this paper
• Current strategic trends in drug discovery: the present as prologue

  2023cites this paper
• Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment

  2022cites this paper
• Cannabinoid receptor 1 positive allosteric modulator (GAT229) attenuates cisplatin-induced neuropathic pain in mice

  2022cites this paper
• In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator?

  2022cites this paper
• CB1R, CB2R and TRPV1 expression and modulation in in vivo, animal glaucoma models: A systematic review.

  2022cites this paper
• Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy.

  2021cites this paper
• CB1 Cannabinoid Receptor Signaling and Biased Signaling

  2021cites this paper
• Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801 on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task.

  2020cites this paper
• Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward

  2020cites this paper
• Molecular Mechanism and Cannabinoid Pharmacology.

  2020cites this paper
• Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation

  2020cites this paper
• Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist

  2020cites this paper
• Evidence that cannabinoid CB1 receptors regulate intraocular pressure via two opposing mechanisms.

  2020cites this paper
• Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model

  2019cites this paper
• Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.

  2019cites this paper
• Application of Fluorine- And Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of CB1 Receptor Positive Allosteric Modulators.

  2019cites this paper
• The future of type 1 cannabinoid receptor allosteric ligands

  2018cites this paper
• Factors influencing the specificity and bias of CB1 cannabinoid receptor signalling

  2018cites this paper
• Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options

  2018influential citation
• Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor

  2018cites this paper
• Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors

  2018cites this paper